{"id":357188,"date":"2025-08-29T10:07:28","date_gmt":"2025-08-29T10:07:28","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-rapport-therapeutics\/"},"modified":"2025-08-29T10:07:28","modified_gmt":"2025-08-29T10:07:28","slug":"how-to-buy-rapport-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/","title":{"rendered":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-357188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Rapport Therapeutics (RAPP) hisseleri nas\u0131l al\u0131n\u0131r ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Rapport Therapeutics (RAPP) hisseleri nas\u0131l al\u0131n\u0131r ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Rapport Therapeutics (RAPP), devrim niteli\u011finde \u00f6zg\u00fcll\u00fckle beyin bozukluklar\u0131n\u0131 hedefleyen hassas n\u00f6robilim alan\u0131nda \u00f6nc\u00fc konumdad\u0131r. Eyl\u00fcl 2025'te gelecek Faz 2 deneme sonu\u00e7lar\u0131yla, bu hisse \u00f6nemli bir hareketlilik ya\u015fayabilir. G\u00fcncel fiyatlardan ad\u0131m ad\u0131m sat\u0131n alma stratejilerine kadar her \u015feyi detayland\u0131raca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Rapport Therapeutics (RAPP), devrim niteli\u011finde \u00f6zg\u00fcll\u00fckle beyin bozukluklar\u0131n\u0131 hedefleyen hassas n\u00f6robilim alan\u0131nda \u00f6nc\u00fc konumdad\u0131r. Eyl\u00fcl 2025'te gelecek Faz 2 deneme sonu\u00e7lar\u0131yla, bu hisse \u00f6nemli bir hareketlilik ya\u015fayabilir. G\u00fcncel fiyatlardan ad\u0131m ad\u0131m sat\u0131n alma stratejilerine kadar her \u015feyi detayland\u0131raca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla, Rapport Therapeutics (RAPP) NASDAQ'ta <strong>14,63 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Eyl\u00fcl 2025 kesinlikle kritik<\/strong>\u2014\u015firket, ila\u00e7 diren\u00e7li epilepsi i\u00e7in lider ila\u00e7lar\u0131 RAP-219'un Faz 2a deneme sonu\u00e7lar\u0131n\u0131 bu tarihte a\u00e7\u0131klayacak.<\/p> <p><strong>Neden Eyl\u00fcl \u00d6nemli:<\/strong><br\/> Tarihsel olarak, biyoteknoloji hisseleri klinik deneme sonu\u00e7lar\u0131 etraf\u0131nda b\u00fcy\u00fck fiyat dalgalanmalar\u0131 ya\u015far. Rapport, 7 A\u011fustos 2025'te a\u00e7\u0131klad\u0131\u011f\u0131 2. \u00e7eyrek kazan\u00e7lar\u0131nda beklentileri a\u015farak hisse ba\u015f\u0131na 0,75 $ zarar bildirdi; beklenen zarar ise 0,85 $ idi (<a href=\"https:\/\/www.chartmill.com\/news\/RAPP\/Chartmill-32659-Rapport-Therapeutics-Inc-NASDAQRAPP-Reports-Narrower-Than-Expected-Q2-2025-Loss-Amid-Clinical-Progress\">Chartmill<\/a>). Hisse hafif\u00e7e y\u00fckseldi, ancak as\u0131l hareket Eyl\u00fcl verileriyle gelecek.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Diplerden \u0130yile\u015fmeye<\/h2> <p>RAPP tam bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131! \u0130\u015fte son alt\u0131 ayda olanlar:<\/p> <p><strong>Mart 2025:<\/strong> En d\u00fc\u015f\u00fck seviye olan <strong>6,43 $<\/strong>'a geriledi (<a href=\"https:\/\/www.tradingview.com\/symbols\/NASDAQ-RAPP\/\">TradingView<\/a>). Yat\u0131r\u0131mc\u0131lar nakit t\u00fcketimi ve klinik zaman \u00e7izelgeleri konusunda endi\u015feliydi.<\/p> <p><strong>May\u0131s-Haziran 2025:<\/strong> \u015eirketin olumlu Faz 1 g\u00fcvenlik verilerini a\u00e7\u0131klamas\u0131 ve denemelere devam etmesiyle <strong>8-12 $ aral\u0131\u011f\u0131nda<\/strong> istikrarl\u0131 bir toparlanma ya\u015fand\u0131.<\/p> <p><strong>A\u011fustos 2025:<\/strong> Beklenenden iyi gelen 2. \u00e7eyrek kazan\u00e7lar ve Faz 2a deneme kay\u0131tlar\u0131n\u0131n tamamlanmas\u0131 sonras\u0131 <strong>14-16 $<\/strong> civar\u0131nda stabil hale geldi.<\/p> <p><strong>Son 3 ayl\u0131k performans +%34,26 art\u0131\u015f g\u00f6steriyor<\/strong> (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/RAPP\/chart\/\">MarketBeat<\/a>), bu da kritik Eyl\u00fcl kataliz\u00f6r\u00fcne g\u00fc\u00e7l\u00fc bir momentumla girildi\u011fini g\u00f6steriyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 (Y\u0131l Sonu): 19-22 $<\/strong> - Eyl\u00fcl deneme sonu\u00e7lar\u0131 olumlu olursa h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 g\u00f6r\u00fclebilir. Sonu\u00e7lar kar\u0131\u015f\u0131k olursa muhafazakar tahmin.<\/li> <li><strong>2026: 25-30 $<\/strong> - Ba\u015far\u0131l\u0131 Faz 2 verilerinin geni\u015fletilmi\u015f denemelere ve potansiyel ortakl\u0131k g\u00f6r\u00fc\u015fmelerine yol a\u00e7mas\u0131 varsay\u0131l\u0131yor.<\/li> <li><strong>2028: 40-50 $<\/strong> - Lider endikasyon i\u00e7in olas\u0131 FDA onay zaman \u00e7izelgesi, \u00f6nemli de\u011fer yarat\u0131m\u0131 sa\u011flar.<\/li> <li><strong>2030: 60 $+<\/strong> - Birden fazla onaylanm\u0131\u015f endikasyon ve b\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi.<\/li> <\/ul> <p><strong>Sonu\u00e7: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong>. Eyl\u00fcl kataliz\u00f6r\u00fc d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc olabilir.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong> - Faz 2 sonu\u00e7lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir (%40-50 d\u00fc\u015f\u00fc\u015f m\u00fcmk\u00fcn)<\/li> <li><strong>Nakit t\u00fcketimi<\/strong> - 2026'ya kadar 260 milyon $ nakit rezervi var, ancak Ar-Ge maliyetleri art\u0131yor<\/li> <li><strong>Reg\u00fclasyon engelleri<\/strong> - FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemez<\/li> <li><strong>Rekabet<\/strong> - Benzer n\u00f6rolojik durumlar\u0131 hedefleyen di\u011fer \u015firketler<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>Eyl\u00fcl kataliz\u00f6r\u00fc<\/strong> - Faz 2 sonu\u00e7lar\u0131 %100'\u00fcn \u00fczerinde kazan\u00e7 sa\u011flayabilir<\/li> <li><strong>Temiz g\u00fcvenlik profili<\/strong> - Faz 1'de ciddi yan etki yok (<a href=\"https:\/\/www.stocktitan.net\/news\/RAPP\/rapport-therapeutics-reports-second-quarter-2025-financials-and-3wf9w5qi8j45.html\">StockTitan<\/a>)<\/li> <li><strong>Birden fazla endikasyon<\/strong> - Epilepsi, bipolar mani ve n\u00f6ropatik a\u011fr\u0131 programlar\u0131<\/li> <li><strong>G\u00fc\u00e7l\u00fc analist deste\u011fi<\/strong> - Ortalama fiyat hedefi 33,67 $ (y\u00fczde 102 y\u00fckseli\u015f potansiyeli)<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Eyl\u00fcl\u00fc bekleyin<\/strong> - Riskleri azaltmak i\u00e7in deneme sonu\u00e7lar\u0131ndan sonra al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Limit emirleri kullan\u0131n<\/strong> - Maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyerek fazla \u00f6deme yapmaktan ka\u00e7\u0131n\u0131n<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"RAPP ile ticaret yapmak lise a\u015fk\u0131 gibidir\u2014heyecan verici potansiyel ama duygusal sars\u0131nt\u0131ya haz\u0131rl\u0131kl\u0131 olun. Kalbinizi ve portf\u00f6y\u00fcn\u00fcz\u00fc koruyun!\"<\/li> <\/ol>  <h2>\u2705 Rapport Therapeutics (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip olmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"RAPP\" aramas\u0131 yap\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit emri verin<\/td><td>\u0130yi bir giri\u015f noktas\u0131 i\u00e7in 14,50 $ veya daha d\u00fc\u015f\u00fck fiyat belirleyin<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014%1'in alt\u0131nda hedefleyin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong> - Herhangi bir kimlik belgesini y\u00fckleyin ve dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>100'den fazla para \u00e7ekme se\u00e7ene\u011fi<\/strong> - Kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim kaynaklar\u0131, biyoteknoloji yat\u0131r\u0131mlar\u0131na yeni ba\u015flayanlar\u0131n karma\u015f\u0131kl\u0131k olmadan ad\u0131m atmas\u0131n\u0131 sa\u011flar.<\/p>  <h2>\ud83c\udf0d 2025'te Rapport Therapeutics: N\u00f6robilimde Yenilik\u00e7i<\/h2> <p>Rapport Therapeutics, beyin bozukluklar\u0131n\u0131n tedavisinde devrim yarat\u0131yor. Geleneksel ila\u00e7lar\u0131n t\u00fcm beyni etkilemesinin aksine, RAP teknolojileri belirli b\u00f6lgeleri hedefliyor\u2014av t\u00fcfe\u011fi yerine keskin ni\u015fanc\u0131 t\u00fcfe\u011fi kullanmak gibi (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/06\/02\/3092291\/0\/en\/Rapport-Therapeutics-Hosts-Investor-and-Analyst-Day-Provides-Corporate-Updates.html\">GlobeNewswire<\/a>).<\/p> <p>\u015eirketin lider ilac\u0131 RAP-219, 2025 2. \u00e7eyre\u011finde Faz 2a kay\u0131tlar\u0131n\u0131 tamamlad\u0131 ve ila\u00e7 diren\u00e7li epilepsiden muzdarip milyonlara yard\u0131mc\u0131 olabilir. 260,4 milyon $ nakit ile 2026'ya kadar finansman\u0131 sa\u011flanm\u0131\u015f durumda\u2014kritik d\u00f6n\u00fcm noktalar\u0131na ula\u015fmak i\u00e7in yeterli kaynak.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi:<\/strong> 2025'te Rapport bilim insanlar\u0131, teknolojilerinin i\u015fitme bozukluklar\u0131na da uygulanabilece\u011fini ke\u015ffetti; bu da epilepsi ve a\u011fr\u0131 d\u0131\u015f\u0131ndaki tamamen yeni tedavi alanlar\u0131n\u0131n a\u00e7\u0131lmas\u0131n\u0131 sa\u011flad\u0131.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla, Rapport Therapeutics (RAPP) NASDAQ&#8217;ta <strong>14,63 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Eyl\u00fcl 2025 kesinlikle kritik<\/strong>\u2014\u015firket, ila\u00e7 diren\u00e7li epilepsi i\u00e7in lider ila\u00e7lar\u0131 RAP-219&#8217;un Faz 2a deneme sonu\u00e7lar\u0131n\u0131 bu tarihte a\u00e7\u0131klayacak.<\/p>\n<p><strong>Neden Eyl\u00fcl \u00d6nemli:<\/strong><br \/> Tarihsel olarak, biyoteknoloji hisseleri klinik deneme sonu\u00e7lar\u0131 etraf\u0131nda b\u00fcy\u00fck fiyat dalgalanmalar\u0131 ya\u015far. Rapport, 7 A\u011fustos 2025&#8217;te a\u00e7\u0131klad\u0131\u011f\u0131 2. \u00e7eyrek kazan\u00e7lar\u0131nda beklentileri a\u015farak hisse ba\u015f\u0131na 0,75 $ zarar bildirdi; beklenen zarar ise 0,85 $ idi (<a href=\"https:\/\/www.chartmill.com\/news\/RAPP\/Chartmill-32659-Rapport-Therapeutics-Inc-NASDAQRAPP-Reports-Narrower-Than-Expected-Q2-2025-Loss-Amid-Clinical-Progress\">Chartmill<\/a>). Hisse hafif\u00e7e y\u00fckseldi, ancak as\u0131l hareket Eyl\u00fcl verileriyle gelecek.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Diplerden \u0130yile\u015fmeye<\/h2>\n<p>RAPP tam bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131! \u0130\u015fte son alt\u0131 ayda olanlar:<\/p>\n<p><strong>Mart 2025:<\/strong> En d\u00fc\u015f\u00fck seviye olan <strong>6,43 $<\/strong>&#8216;a geriledi (<a href=\"https:\/\/www.tradingview.com\/symbols\/NASDAQ-RAPP\/\">TradingView<\/a>). Yat\u0131r\u0131mc\u0131lar nakit t\u00fcketimi ve klinik zaman \u00e7izelgeleri konusunda endi\u015feliydi.<\/p>\n<p><strong>May\u0131s-Haziran 2025:<\/strong> \u015eirketin olumlu Faz 1 g\u00fcvenlik verilerini a\u00e7\u0131klamas\u0131 ve denemelere devam etmesiyle <strong>8-12 $ aral\u0131\u011f\u0131nda<\/strong> istikrarl\u0131 bir toparlanma ya\u015fand\u0131.<\/p>\n<p><strong>A\u011fustos 2025:<\/strong> Beklenenden iyi gelen 2. \u00e7eyrek kazan\u00e7lar ve Faz 2a deneme kay\u0131tlar\u0131n\u0131n tamamlanmas\u0131 sonras\u0131 <strong>14-16 $<\/strong> civar\u0131nda stabil hale geldi.<\/p>\n<p><strong>Son 3 ayl\u0131k performans +%34,26 art\u0131\u015f g\u00f6steriyor<\/strong> (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/RAPP\/chart\/\">MarketBeat<\/a>), bu da kritik Eyl\u00fcl kataliz\u00f6r\u00fcne g\u00fc\u00e7l\u00fc bir momentumla girildi\u011fini g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu): 19-22 $<\/strong> &#8211; Eyl\u00fcl deneme sonu\u00e7lar\u0131 olumlu olursa h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 g\u00f6r\u00fclebilir. Sonu\u00e7lar kar\u0131\u015f\u0131k olursa muhafazakar tahmin.<\/li>\n<li><strong>2026: 25-30 $<\/strong> &#8211; Ba\u015far\u0131l\u0131 Faz 2 verilerinin geni\u015fletilmi\u015f denemelere ve potansiyel ortakl\u0131k g\u00f6r\u00fc\u015fmelerine yol a\u00e7mas\u0131 varsay\u0131l\u0131yor.<\/li>\n<li><strong>2028: 40-50 $<\/strong> &#8211; Lider endikasyon i\u00e7in olas\u0131 FDA onay zaman \u00e7izelgesi, \u00f6nemli de\u011fer yarat\u0131m\u0131 sa\u011flar.<\/li>\n<li><strong>2030: 60 $+<\/strong> &#8211; Birden fazla onaylanm\u0131\u015f endikasyon ve b\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi.<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong>. Eyl\u00fcl kataliz\u00f6r\u00fc d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc olabilir.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong> &#8211; Faz 2 sonu\u00e7lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir (%40-50 d\u00fc\u015f\u00fc\u015f m\u00fcmk\u00fcn)<\/li>\n<li><strong>Nakit t\u00fcketimi<\/strong> &#8211; 2026&#8217;ya kadar 260 milyon $ nakit rezervi var, ancak Ar-Ge maliyetleri art\u0131yor<\/li>\n<li><strong>Reg\u00fclasyon engelleri<\/strong> &#8211; FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemez<\/li>\n<li><strong>Rekabet<\/strong> &#8211; Benzer n\u00f6rolojik durumlar\u0131 hedefleyen di\u011fer \u015firketler<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>Eyl\u00fcl kataliz\u00f6r\u00fc<\/strong> &#8211; Faz 2 sonu\u00e7lar\u0131 %100&#8217;\u00fcn \u00fczerinde kazan\u00e7 sa\u011flayabilir<\/li>\n<li><strong>Temiz g\u00fcvenlik profili<\/strong> &#8211; Faz 1&#8217;de ciddi yan etki yok (<a href=\"https:\/\/www.stocktitan.net\/news\/RAPP\/rapport-therapeutics-reports-second-quarter-2025-financials-and-3wf9w5qi8j45.html\">StockTitan<\/a>)<\/li>\n<li><strong>Birden fazla endikasyon<\/strong> &#8211; Epilepsi, bipolar mani ve n\u00f6ropatik a\u011fr\u0131 programlar\u0131<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc analist deste\u011fi<\/strong> &#8211; Ortalama fiyat hedefi 33,67 $ (y\u00fczde 102 y\u00fckseli\u015f potansiyeli)<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Eyl\u00fcl\u00fc bekleyin<\/strong> &#8211; Riskleri azaltmak i\u00e7in deneme sonu\u00e7lar\u0131ndan sonra al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Limit emirleri kullan\u0131n<\/strong> &#8211; Maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyerek fazla \u00f6deme yapmaktan ka\u00e7\u0131n\u0131n<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;RAPP ile ticaret yapmak lise a\u015fk\u0131 gibidir\u2014heyecan verici potansiyel ama duygusal sars\u0131nt\u0131ya haz\u0131rl\u0131kl\u0131 olun. Kalbinizi ve portf\u00f6y\u00fcn\u00fcz\u00fc koruyun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Rapport Therapeutics (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;RAPP&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emri verin<\/td>\n<td>\u0130yi bir giri\u015f noktas\u0131 i\u00e7in 14,50 $ veya daha d\u00fc\u015f\u00fck fiyat belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014%1&#8217;in alt\u0131nda hedefleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong> &#8211; Herhangi bir kimlik belgesini y\u00fckleyin ve dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>100&#8217;den fazla para \u00e7ekme se\u00e7ene\u011fi<\/strong> &#8211; Kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim kaynaklar\u0131, biyoteknoloji yat\u0131r\u0131mlar\u0131na yeni ba\u015flayanlar\u0131n karma\u015f\u0131kl\u0131k olmadan ad\u0131m atmas\u0131n\u0131 sa\u011flar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Rapport Therapeutics: N\u00f6robilimde Yenilik\u00e7i<\/h2>\n<p>Rapport Therapeutics, beyin bozukluklar\u0131n\u0131n tedavisinde devrim yarat\u0131yor. Geleneksel ila\u00e7lar\u0131n t\u00fcm beyni etkilemesinin aksine, RAP teknolojileri belirli b\u00f6lgeleri hedefliyor\u2014av t\u00fcfe\u011fi yerine keskin ni\u015fanc\u0131 t\u00fcfe\u011fi kullanmak gibi (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/06\/02\/3092291\/0\/en\/Rapport-Therapeutics-Hosts-Investor-and-Analyst-Day-Provides-Corporate-Updates.html\">GlobeNewswire<\/a>).<\/p>\n<p>\u015eirketin lider ilac\u0131 RAP-219, 2025 2. \u00e7eyre\u011finde Faz 2a kay\u0131tlar\u0131n\u0131 tamamlad\u0131 ve ila\u00e7 diren\u00e7li epilepsiden muzdarip milyonlara yard\u0131mc\u0131 olabilir. 260,4 milyon $ nakit ile 2026&#8217;ya kadar finansman\u0131 sa\u011flanm\u0131\u015f durumda\u2014kritik d\u00f6n\u00fcm noktalar\u0131na ula\u015fmak i\u00e7in yeterli kaynak.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi:<\/strong> 2025&#8217;te Rapport bilim insanlar\u0131, teknolojilerinin i\u015fitme bozukluklar\u0131na da uygulanabilece\u011fini ke\u015ffetti; bu da epilepsi ve a\u011fr\u0131 d\u0131\u015f\u0131ndaki tamamen yeni tedavi alanlar\u0131n\u0131n a\u00e7\u0131lmas\u0131n\u0131 sa\u011flad\u0131.<\/p>\n"},"faq":[{"question":"Rapport Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Rapport Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden RAPP sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Rapport Therapeutics hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri ve rekabet yer almaktad\u0131r. Bu fakt\u00f6rler hisse fiyat\u0131nda dalgalanmalara neden olabilir."},{"question":"Eyl\u00fcl 2025'te neden \u00f6nemli bir geli\u015fme bekleniyor?","answer":"\u015eirket, Eyl\u00fcl 2025'te ila\u00e7 diren\u00e7li epilepsi i\u00e7in lider ila\u00e7 RAP-219'un Faz 2a deneme sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak. Bu sonu\u00e7lar hisse fiyat\u0131nda \u00f6nemli hareketlere yol a\u00e7abilir."},{"question":"Yeni ba\u015flayan biri Rapport Therapeutics hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak ba\u015flay\u0131n, Eyl\u00fcl sonu\u00e7lar\u0131n\u0131 bekleyin, limit emirleri kullanarak fiyat kontrol\u00fc sa\u011flay\u0131n ve y\u00fcksek riskleri g\u00f6z \u00f6n\u00fcnde bulundurun."},{"question":"Pocket Option platformu neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygun?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunar. Kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim materyalleri ile yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Rapport Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Rapport Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden RAPP sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Rapport Therapeutics hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri ve rekabet yer almaktad\u0131r. Bu fakt\u00f6rler hisse fiyat\u0131nda dalgalanmalara neden olabilir."},{"question":"Eyl\u00fcl 2025'te neden \u00f6nemli bir geli\u015fme bekleniyor?","answer":"\u015eirket, Eyl\u00fcl 2025'te ila\u00e7 diren\u00e7li epilepsi i\u00e7in lider ila\u00e7 RAP-219'un Faz 2a deneme sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak. Bu sonu\u00e7lar hisse fiyat\u0131nda \u00f6nemli hareketlere yol a\u00e7abilir."},{"question":"Yeni ba\u015flayan biri Rapport Therapeutics hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak ba\u015flay\u0131n, Eyl\u00fcl sonu\u00e7lar\u0131n\u0131 bekleyin, limit emirleri kullanarak fiyat kontrol\u00fc sa\u011flay\u0131n ve y\u00fcksek riskleri g\u00f6z \u00f6n\u00fcnde bulundurun."},{"question":"Pocket Option platformu neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygun?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunar. Kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim materyalleri ile yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T10:07:28+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T10:07:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\",\"name\":\"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"datePublished\":\"2025-08-29T10:07:28+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T10:07:28+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T10:07:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/","name":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","datePublished":"2025-08-29T10:07:28+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-rapport-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Rapport Therapeutics, Inc. (RAPP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Rapport Therapeutics, Inc. (RAPP) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":357191,"slug":"how-to-buy-rapport-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Rapport Therapeutics, Inc. (RAPP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Rapport Therapeutics, Inc. (RAPP)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-rapport-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":357187,"slug":"how-to-buy-rapport-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Rapport Therapeutics, Inc. (RAPP) - Investimento em a\u00e7\u00f5es da Rapport Therapeutics, Inc. (RAPP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-rapport-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=357188"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334036"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=357188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=357188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=357188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}